Fosomax, Zometa and Aredia Medication Users Suing For Health Damages
Since 2003, several cases of bisphosphonate associated osteonecrosis of the jaw (BON) have surfaced. Bisphosphonates, like Fosamax, Zometa and Aredia, are largely used to treat and prevent osteoporosis and cancer. However, these medications also carry risks of severe side effects, like osteonecrosis.
Osteonecrosis occurs when bones lose their blood supply and eventually die. Osteonecrosis of the jaw often causes pain, swelling, infection, loosening of the teeth, exposed bone and drainage. Early on, symptoms of this rare jaw disorder may not be apparent, but upon maturation of the disease pain will become increasingly severe and debilitating. St. Louis product liability lawsuits and legal claims related to Osteonocrosis are becoming more prevalent by users of Fosomax, Zometa, and Aredia.
Fosamax has recently come under scrutiny for its association with causing this severe jaw disorder. The majority of cases where Fosamax was reportedly a factor in causing osteonecrosis of the jaw involved people with cancer who were receiving chemotherapy. Additionally, people with active dental diseases or those who had recently undergone a dental procedure, like tooth extraction, also saw increased chances of developing this disease.
Although the chance of developing osteonecrosis from taking Fosamax is lower in people without cancer or dental problems, risks are still present. If you have bone exposure or have experienced jaw pain after taking Fosamax, it is crucial that you seek medical attention. It is also crucial to seek legal representation from an experienced Missouri personal injury lawyer immediately. Call the personal injury lawyers at Page Cagle for a free consultation to discuss your case. The personal injury attorneys at Page Cagle have been aggressively representing injured clients for the entirety of their existence.
Call 24 hours a day at 314.322.8515 or toll free at 1.800.500.INJURY (4658) to speak to a skilled Missouri personal injury attorney. You can also email John Page, a partner at Page Cagle, at john@pagecagle.com.
